Now I have a thorough understanding of the paper and the reviews. Let me produce the final consolidated review.

## Summary

This paper introduces Adaptive Shrinkage Estimation for personalized Deep Kernel Regression (pers-DKGP), combining a population-level deep GP with a subject-specific GP via a learned weighting α. The method is designed for longitudinal brain volumetry prediction from high-dimensional multimodal inputs. It is evaluated on a large multi-study dataset (2,200 subjects from iSTAGING) and validated on three external clinical cohorts (AIBL, OASIS, PreventAD), consistently outperforming LMM, GAM, Deep Regression, and DME baselines.

## Strengths

1. **Adaptive α demonstrably outperforms constant and deterministic alternatives.** The ablation study (Section 3.6, Table 1) shows the XGBoost-learned α yields lower MAE than any constant α (e.g., Hippocampus R: MAE 0.141 vs. best constant 0.159; Thalamus Proper: 0.090 vs. 0.095). This directly validates the paper's core claim that adaptive shrinkage improves personalization.

2. **Consistent predictive gains across diverse disease statuses and ROIs.** In Section 3.3, the percentage MAE differences against LMM are large and consistent: 177.66% for AD subjects, 22.05% for AD progressors, 29.78% for healthy controls, across 6 brain ROIs. These differences, backed by 95% CIs in Figure 2, provide concrete evidence that the framework captures nonlinear patterns the baselines miss.

3. **Strong generalization to three external clinical studies with different demographics and follow-up protocols.** Section 3.5 uses a clean protocol (personalize from the first follow-up, predict the rest) on AIBL (Mean AE 0.197±0.009), OASIS (0.259±0.006), and PreventAD (0.139±0.004), all uniformly better than baselines with narrow confidence intervals. This is the strongest evidence in the paper—it demonstrates robustness across heterogeneous real-world settings.

4. **Explainability analysis supports the intuitive behavior of the model.** The SHAP analysis (Supplementary D.3, Figure 8) identifies observation time (T_obs) as the most influential feature, with correlation analysis showing that when the deviation between population and subject-specific predictions is large, predicted α decreases with longer follow-up—exactly the expected behavior: more trust in subject-specific data as evidence accumulates.

## Weaknesses

### Fatal
None.

### Major

None.

### Minor

1. **The α target is optimized over full trajectories on the validation set, which may not be optimal for future-only prediction.** In Section 2.5, Eq. 10 minimizes reconstruction error over the *entire* trajectory (t=0 to t_n) of validation subjects, including the portion the ss-DKGP fits almost perfectly. The XGBoost is then trained to predict this α from features available at inference time. The concern is that the optimal α for full-trajectory reconstruction may systematically differ from the α optimal for future-only prediction, because the observed portion pulls α toward 0 (where ss-DKGP fits near-perfectly). While this does not constitute data leakage (test subjects are held out, and the XGBoost features contain no future information), the paper does not validate that the learned α function is near-optimal for future-point prediction. The authors should show on the validation set that α targets computed under future-point-only MSE correlate well with those computed under full-trajectory MSE, or adopt a temporal-holdout scheme.

2. **The phrase "unseen trajectory" in the main evaluation is ambiguous.** Section 3.2 states metrics are "calculated over the entire unseen trajectory of the test subjects." It is not explicitly stated whether this includes the observed time points used for ss-DKGP personalization. Figure 2(bottom) clearly evaluates from "time from last observation" (future-only), and the external validation protocol (Section 3.5) is exemplary in its clarity. However, the summary statistics in Figure 2(top) and Table 1 do not specify the evaluation horizon. The paper should explicitly disambiguate this in every table and figure.

3. **The independence assumption for variance combination is acknowledged but unvalidated.** Equation 9 assumes independence between p-DKGP and ss-DKGP to compute the combined variance. The authors transparently note this in the Discussion (Section 4), stating it affects only uncertainty quantification, not the predictive mean. However, since the paper reports interval width and coverage, validating this assumption (or comparing against a conservative covariance estimate) would strengthen the uncertainty-quantification claims.

4. **The baseline set omits modern irregular-time-series methods.** The comparisons include LMM, GAM, Deep Regression, and DME (Chung et al., 2019). While these are reasonable within the neuroimaging application domain, the set is narrow for a 2026 paper. Methods such as Neural ODEs (Latent ODEs, ODE-RNN) or Deep State Space Models that are designed for irregularly-sampled longitudinal data are absent. The external validation partially mitigates this concern by demonstrating generalization, but including at least one such method or providing a principled justification for their exclusion would significantly strengthen the paper.

### Trivial
- The 177.66% LMM MAE difference for AD subjects (Section 3.3) is reported without explaining the metric (it is the relative difference (LMM−pers-DKGP)/pers-DKGP × 100, so LMM error is ~2.78× larger). This is not implausible given the nonlinear AD trajectories, but clarifying the computation would avoid confusion.

## Nice-to-Haves

- Report training time and inference time per new subject to give a practical sense of computational cost.
- For applied clinical use, show how the method performs with fewer observations (e.g., 2–3 follow-ups) since many cohorts have sparse follow-up.
- Report the latent dimension L and MLP structure used for the deep kernel transformation.

## Removed Points

These points were raised by reviewers but removed per the filtering rules:

- **Missing hyperparameters (learning rate, optimizer, epochs):** Likely in the supplement, which is stripped by the parser. Hard Rule: remove criticisms about missing appendix content.
- **"177% seems implausibly large; could be a typo":** The 177.66% figure is mathematically plausible as a relative percentage difference (LMM MAE ≈ 2.78× pers-DKGP MAE). The reviewer's speculation about a typo is not a verifiable weakness — removed as a strawman.
- **"Comparison to simpler Bayesian hierarchical shrinkage":** This is a methodologically different approach that the paper does not claim to address. Removing per scope-creep filtering.
- **Strength Finder strengths about "important problem" framing:** Generic framing removed; only evidence-backed strengths retained.
- **General "not yet released / cannot be independently verified" style concerns:** Hard Rule removes these, as all cited entities are assumed to exist.
- **"The regression target is unrealistic because it exploits future knowledge":** Removed because the XGBoost does *not* have access to future information (features are {y_p, y_s, v_p, v_s, T_obs}). The concern is about optimality of the target, not information leakage. This is kept as a Minor weakness (point 1 above) but the reviewer's framing as potential evaluation bias overstates the issue.

## Novel Insights

The most interesting insight emerging from the reviews is not captured in the paper itself: the two-stage design (compute oracle α from full trajectories on the validation set, then regress it from available features) is a clever way to "amortize" a hindsight-optimal weighting function into an inference-time predictor. The disconnect between the training target (full-trajectory MSE) and the deployment objective (future-only MSE) is actually a feature, not a bug, if the XGBoost learns the *relative* ranking of population vs. subject-specific reliability rather than the precise numerical α. The consistently strong results, especially on external cohorts where the α function must extrapolate to new data distributions, suggest the XGBoost is learning a robust signal. Future work could formalize this as a bilevel optimization or an implicit loss.

## Suggestions

1. **Clarify the evaluation horizon explicitly.** In Table 1 and Figure 2(top), state clearly whether metrics include observed time points or are future-only. If they are already future-only (as the evidence suggests), say so directly. If they mix observed and future points, re-run on future-only and report both.

2. **Validate the α target on validation subjects.** Compute optimal α under the full-trajectory objective (current) and under a future-points-only objective, and show that the XGBoost trained on the former produces predictions comparable to the latter on test subjects. This would resolve the main methodological concern.

3. **Add a sensitivity analysis for the independence assumption.** Compare the reported coverage/interval-width against a combined variance that assumes some positive correlation (e.g., a grid of ρ values) to bound the potential over- or under-confidence.

4. **Include at least one modern irregular-time-series baseline** (e.g., a Neural ODE) in the supplement, or provide a clear domain-specific justification for why such methods are not applicable to this high-dimensional multimodal prediction setting.

## Score and Decision

**Originality:** The adaptive shrinkage estimation via XGBoost-regressed α is a novel design for combining population and subject-specific GP predictions, building on prior personalization approaches (Rudovic et al., 2019; Chung et al., 2019) with a distinct two-stage learning strategy.

**Importance of research question:** Highly relevant. Longitudinal brain trajectory prediction is critical for tracking neurodegeneration, designing clinical trials, and treatment effect estimation. The problem of personalizing predictions from high-dimensional multimodal inputs with irregular follow-ups is practically important.

**Claims well-supported:** Yes, for the core claims. The ablation study supports the adaptive α, the main results show consistent improvement over baselines, and the external validation is strong. The one ambiguity (α target definition) is a methodological nuance that warrants clarification but does not undermine the paper's conclusions.

**Soundness of experiments:** Generally sound. The dataset size (2,200 subjects, 1,560/200/440 split) is adequate. The external validation protocol is exemplary. The main ambiguity is the evaluation horizon wording and the α target definition; both are fixable with clarifications.

**Clarity of writing:** Clear overall. The methodology is well-described. The figures are informative. Some specifics (α target objective, evaluation horizon) need sharper language.

**Value to the research community:** Practical contribution with immediate applicability. The framework addresses a real need in clinical neuroimaging. The code and model availability (presumably post-publication) would increase its value.

MY FINAL SCORE: <score>7.5</score>
MY FINAL DECISION: <decision>Accept</decision>